Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
Australia
Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria One Clinical Research, Nedlands, Western Australia China
Hunan Cancer Hospital, Changsha, Hunan Affiliated Hospital of Hebei University, Baoding Cancer Hospital Chinese Academy of Medical Sciences, Beijing The First Affiliated Hospital of Bengbu Medical College, Bengbu Zhujiang Hospital of Southern Medical University, Guangzhou The Affiliated Tumour Hospital of Harbin Medical University, Harbin Shandong Cancer Hospital, Shandong Tianjin Medical University Cancer Institue & Hospital, Tianjin